MP
AKBA icon

Mangrove Partners’s Akebia Therapeutics AKBA Stock Holding History

Mangrove Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$523K Buy
+375,954
New +$517K 0.04% 185

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mangrove Partners's AKBA Position: Q1 2026 in Review

Mangrove Partners opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 375,954 shares worth $523K. The stake represents 0.04% of the portfolio and ranks #185 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Mangrove Partners held 375,954 shares of Akebia Therapeutics worth $523K as of Q1 2026.
  • Akebia Therapeutics was a new Mangrove Partners position in Q1 2026.
  • Akebia Therapeutics made up 0.04% of Mangrove Partners's portfolio in Q1 2026, its #185 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.